3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
Animals
CREB-Binding Protein
/ genetics
Carcinogenesis
/ genetics
Cell Proliferation
/ genetics
Cells, Cultured
Drug Screening Assays, Antitumor
/ methods
Female
Genomics
/ methods
HCT116 Cells
HEK293 Cells
Humans
Mice
Mice, Inbred NOD
Mice, Nude
Molecular Targeted Therapy
Mutation
Neoplasm Invasiveness
Protein Kinase Inhibitors
/ pharmacology
Triple Negative Breast Neoplasms
/ genetics
Xenograft Model Antitumor Assays
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
15 02 2021
15 02 2021
Historique:
received:
29
05
2020
revised:
12
10
2020
accepted:
25
11
2020
pubmed:
30
1
2021
medline:
13
5
2021
entrez:
29
1
2021
Statut:
ppublish
Résumé
Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies for this hard-to-treat patient population, yet studies using high-throughput and accurate models to define the functions of driver genes in TNBC to date have been limited. Here, we employed unbiased functional genomics screening of the 200 most frequently mutated genes in breast cancer, using spheroid cultures to model
Identifiants
pubmed: 33509944
pii: 0008-5472.CAN-20-1822
doi: 10.1158/0008-5472.CAN-20-1822
pmc: PMC7611219
mid: EMS128555
doi:
Substances chimiques
Protein Kinase Inhibitors
0
CREB-Binding Protein
EC 2.3.1.48
CREBBP protein, human
EC 2.3.1.48
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
847-859Subventions
Organisme : Breast Cancer Now
ID : 2017JULYPCC005
Pays : United Kingdom
Organisme : Breast Cancer Now
ID : BREAST CANCER NOW RESEARCH CENTRE
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_18051
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom
Informations de copyright
©2021 American Association for Cancer Research.
Références
Nature. 2012 May 16;486(7403):400-4
pubmed: 22722201
Cancer Discov. 2018 Nov;8(11):1422-1437
pubmed: 30181244
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Nucleic Acids Res. 2015 Jan;43(Database issue):D512-20
pubmed: 25514926
Nature. 2020 Apr;580(7801):136-141
pubmed: 32238925
Oncotarget. 2016 Sep 13;7(37):60366-60382
pubmed: 27542221
Nat Genet. 2012 Oct;44(10):1104-10
pubmed: 22941188
Nature. 2011 Mar 10;471(7337):235-9
pubmed: 21390130
Cell Rep. 2018 Mar 13;22(11):2978-2994
pubmed: 29539425
Cancer Cell. 2018 Dec 10;34(6):939-953.e9
pubmed: 30472020
Cancer Cell. 2018 Sep 10;34(3):427-438.e6
pubmed: 30205045
Br J Cancer. 2010 Jan 19;102(2):428-35
pubmed: 20087356
N Engl J Med. 2015 Feb 26;372(9):793-5
pubmed: 25635347
J Vis Exp. 2016 Dec 26;(118):
pubmed: 28060271
Oncoimmunology. 2020 Apr 16;9(1):1750750
pubmed: 32363122
Cancer Res. 2018 Feb 1;78(3):769-780
pubmed: 29229604
BMC Bioinformatics. 2011 Feb 15;12 Suppl 1:S22
pubmed: 21342552
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Annu Rev Med. 2015;66:455-70
pubmed: 25341009
Nat Methods. 2017 Oct;14(10):979-982
pubmed: 28825705
Nature. 2010 Apr 15;464(7291):999-1005
pubmed: 20393555
Cell Rep. 2013 Sep 26;4(6):1116-30
pubmed: 24055055
Cancer Discov. 2016 Apr;6(4):430-45
pubmed: 26603525
Nucleic Acids Res. 2009 Jan;37(Database issue):D623-8
pubmed: 18940869
Bioinformatics. 2012 Jun 1;28(11):1546-8
pubmed: 22513995
Nat Rev Clin Oncol. 2018 Sep;15(9):564-576
pubmed: 29955114
Cancer Cell. 2015 Jan 12;27(1):57-71
pubmed: 25584894
Nature. 2012 Jun 20;486(7403):405-9
pubmed: 22722202
Nat Commun. 2020 Feb 5;11(1):737
pubmed: 32024819
J Clin Invest. 2008 Dec;118(12):3930-42
pubmed: 19033663
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Genome Biol. 2010;11(10):R106
pubmed: 20979621
Cancer Metab. 2016 Apr 01;4:6
pubmed: 27042297
J Thorac Oncol. 2019 Oct;14(10):1853-1859
pubmed: 31302234
J Pathol. 2016 Nov;240(3):315-328
pubmed: 27512948
Cancer Res. 2017 Nov 15;77(22):6340-6352
pubmed: 28947417
Cancer Cell. 2011 Nov 15;20(5):620-34
pubmed: 22094256
Nature. 2011 Mar 10;471(7337):189-95
pubmed: 21390126
EMBO J. 1996 Dec 16;15(24):7060-9
pubmed: 9003781
Nature. 2017 Oct 5;550(7674):128-132
pubmed: 28953875
Clin Cancer Res. 2019 Jan 1;25(1):390-402
pubmed: 30242024
Cell Cycle. 2009 Feb 1;8(3):498-504
pubmed: 19177017
Nature. 2012 Apr 04;486(7403):395-9
pubmed: 22495314
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745
Science. 2019 Mar 15;363(6432):1217-1222
pubmed: 30872525
J Clin Oncol. 2017 Apr 1;35(10):1049-1060
pubmed: 28135148
Cancer Discov. 2019 Jan;9(1):46-63
pubmed: 30266815
Nature. 2009 Oct 8;461(7265):809-13
pubmed: 19812674
Genome Biol. 2013 Jan 24;14(1):R6
pubmed: 23347430
Cell. 2015 Oct 8;163(2):506-19
pubmed: 26451490
Nature. 1996 Dec 19-26;384(6610):641-3
pubmed: 8967953
Cancer Discov. 2017 Mar;7(3):322-337
pubmed: 28069569
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Clin Cancer Res. 2013 Oct 1;19(19):5533-40
pubmed: 23948975